Javascript must be enabled to continue!
Equivalent Mass Versus Life Cycle Cost for Life Support Technology Selection
View through CrossRef
<div class="htmlview paragraph">The decision to develop a particular life support technology or to select it for flight usually depends on the cost to develop and fly it. Other criteria such as performance, safety, reliability, crew time, and technical and schedule risk are considered, but cost is always an important factor. Because launch cost would account for much of the cost of a future planetary mission, and because launch cost is directly proportional to the mass launched, equivalent mass has been used instead of cost to select advanced life support technology. The equivalent mass of a life support system includes the estimated mass of the hardware and of the spacecraft pressurized volume, power supply, and cooling system that the hardware requires. The equivalent mass of a system is defined as the total payload launch mass needed to provide and support the system. An extension of equivalent mass, Equivalent System Mass (ESM), has been established for use in the Advanced Life Support project. ESM adds a mass-equivalent of crew time and possibly other cost factors to equivalent mass. Traditional equivalent mass is strictly based on flown mass and reflects only the launch cost. ESM includes other important cost factors, but it complicates the simple “flown mass” definition of equivalent mass by adding a non-physical mass penalty for crew time that may exceed the actual flown mass. Equivalent mass is used only in life support analysis. Life Cycle Cost (LCC) is much more commonly used. LCC includes DDT&E, launch, and operations costs. For Earth orbit rather than planetary missions, the launch cost is less than the cost of Design, Development, Test, and Evaluation (DDT&E). LCC is a more inclusive cost estimator than equivalent mass. The relative costs of development, launch, and operations vary depending on the mission destination and duration. Since DDT&E or operations may cost more than launch, LCC gives a more accurate relative cost ranking than equivalent mass. To select the lowest cost technology for a particular application we should use LCC rather than equivalent mass.</div>
Title: Equivalent Mass Versus Life Cycle Cost for Life Support Technology Selection
Description:
<div class="htmlview paragraph">The decision to develop a particular life support technology or to select it for flight usually depends on the cost to develop and fly it.
Other criteria such as performance, safety, reliability, crew time, and technical and schedule risk are considered, but cost is always an important factor.
Because launch cost would account for much of the cost of a future planetary mission, and because launch cost is directly proportional to the mass launched, equivalent mass has been used instead of cost to select advanced life support technology.
The equivalent mass of a life support system includes the estimated mass of the hardware and of the spacecraft pressurized volume, power supply, and cooling system that the hardware requires.
The equivalent mass of a system is defined as the total payload launch mass needed to provide and support the system.
An extension of equivalent mass, Equivalent System Mass (ESM), has been established for use in the Advanced Life Support project.
ESM adds a mass-equivalent of crew time and possibly other cost factors to equivalent mass.
Traditional equivalent mass is strictly based on flown mass and reflects only the launch cost.
ESM includes other important cost factors, but it complicates the simple “flown mass” definition of equivalent mass by adding a non-physical mass penalty for crew time that may exceed the actual flown mass.
Equivalent mass is used only in life support analysis.
Life Cycle Cost (LCC) is much more commonly used.
LCC includes DDT&E, launch, and operations costs.
For Earth orbit rather than planetary missions, the launch cost is less than the cost of Design, Development, Test, and Evaluation (DDT&E).
LCC is a more inclusive cost estimator than equivalent mass.
The relative costs of development, launch, and operations vary depending on the mission destination and duration.
Since DDT&E or operations may cost more than launch, LCC gives a more accurate relative cost ranking than equivalent mass.
To select the lowest cost technology for a particular application we should use LCC rather than equivalent mass.
</div>.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
The Black Mass as Play: Dennis Wheatley's The Devil Rides Out
The Black Mass as Play: Dennis Wheatley's The Devil Rides Out
Literature—at least serious literature—is something that we work at. This is especially true within the academy. Literature departments are places where workers labour over texts c...
7
th
International Symposium on Enabling Technologies for Life Sciences (ETP)
7
th
International Symposium on Enabling Technologies for Life Sciences (ETP)
The seventh in the series of ETP Symposia (see
Rapid Communications in Mass Spectrometry
2012,
26
, ...
Peningkatan Prestasi Belajar Materi Bilangan Berpangkat Melalui Model Discovery Learning
Peningkatan Prestasi Belajar Materi Bilangan Berpangkat Melalui Model Discovery Learning
This research is motivated by the unoptimally the mastery of the material is still not optimal exponential number among learners and implementation Discovery learning in mathematic...
Selection Gradients
Selection Gradients
Natural selection and sexual selection are important evolutionary processes that can shape the phenotypic distributions of natural populations and, consequently, a primary goal of ...

